Gail J. Roboz
NewYork–Presbyterian Hospital
444 Papers
1.6K Citations
Gail J. Roboz is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 53, co-authored 339 publications. Previous affiliations of Gail J. Roboz include Cornell University & Boston Medical Center.
Chat about Author
Papers
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.
Nicole M. Cruz,Mayumi Sugita,Nathan Ewing-Crystal,Linda Lam,Roman Galetto,Agnès Gouble,Julianne Smith,Duane C. Hassane,Gail J. Roboz,Monica L. Guzman +9 more
TL;DR: Acute myelogenous leukemia (AML) is a deadly disease characterized by high relapse rates even in patients who initially achieve complete remission.
13
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles
Gail J. Roboz,Hartmut Döhner,Marco Gobbi,Patricia Kropf,Jiri Mayer,Jürgen Krauter,Tadeusz Robak,Hagop M. Kantarjian,Jan Novák,Wiesław Wiktor Jędrzejczak,Xavier Thomas,Mario Ojeda-Uribe,Yasushi Miyazaki,Yoo Hong Min,Su-Peng Yeh,Joseph Brandwein,Liana Gercheva,Judit Demeter,Elizabeth A. Griffiths,Karen W.L. Yee,Jean Pierre J. Issa,Yong Hao,Mohammad Azab,Pierre Fenaux +23 more
TL;DR: Characteristics of patients who received at least 4 or 6 cycles were also well balanced between the 2 treatment arms for age, PS 2-3, secondary AML, poor risk cytogenetics, BM blasts >30%, and proliferative AML (total white cell count ≥20,000/uL).
13
Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.
Azra Raza,Joseph G. Jurcic,Gail J. Roboz,Michael B. Maris,Joseph Stephenson,Brent L. Wood,Bhaskar Rege,Laurie E. Grove,Jonathan G. Drachman,Eric L. Sievers +9 more
TL;DR: Given the responses observed in the context of an excellent tolerability profile, SGN-33 holds promise, as single agent or as part of combination therapy, for the treatment of patients with myeloid malignancy who are ineligible for aggressive therapy.
13
Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.
Gail J. Roboz,Stephen A. Strickland,Mark R. Litzow,Andrew Dalovisio,Alexander E. Perl,Gaetano Bonifacio,Kelly Haines,Alysha Barbera,Das Purkayastha,Kendra Sweet +9 more
TL;DR: Midostaurin demonstrated a manageable safety profile and was associated with high transplant and low on-treatment relapse rates, and toxicities were not influenced by age, anthracycline choice, or coadministration of CYP3A4 inhibitors.
13
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Judith E. Karp,Karen S. Flatten,Eric J. Feldman,J. Greer,D. Loegering,Rebecca M. Ricklis,Lawrence E. Morris,Ellen K. Ritchie,B. D. Smith,Valerie Ironside,Timothy Talbott,Gail J. Roboz,Son B. Le,Xue Wei Meng,Paula A. Schneider,Nga T. Dai,Alex A. Adjei,Steven D. Gore,Mark J. Levis,John J. Wright,Elizabeth Garrett-Mayer,Scott H. Kaufmann +21 more
13